Zenas BioPharma, Inc. (NASDAQ:ZBIO) Receives Average Rating of “Moderate Buy” from Analysts

Zenas BioPharma, Inc. (NASDAQ:ZBIO) has been given an average recommendation of “Moderate Buy” by the nine analysts that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $44.2857.

ZBIO has been the topic of a number of recent analyst reports. Morgan Stanley increased their price objective on Zenas BioPharma from $21.00 to $22.00 and gave the company an “equal weight” rating in a report on Thursday, May 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Zenas BioPharma in a research note on Wednesday, June 24th. Guggenheim upped their price target on Zenas BioPharma from $45.00 to $55.00 and gave the company a “buy” rating in a report on Monday, March 16th. Citigroup reiterated a “buy” rating on shares of Zenas BioPharma in a research note on Wednesday, June 3rd. Finally, Zacks Research upgraded shares of Zenas BioPharma from a “strong sell” rating to a “hold” rating in a research note on Friday, May 15th.

Zenas BioPharma Stock Performance

NASDAQ:ZBIO opened at $27.23 on Friday. The firm has a market capitalization of $1.72 billion, a PE ratio of -3.21 and a beta of -0.96. The business’s fifty day moving average price is $19.90 and its 200 day moving average price is $23.00. The company has a debt-to-equity ratio of 1.04, a current ratio of 11.94 and a quick ratio of 11.94. Zenas BioPharma has a 12 month low of $9.21 and a 12 month high of $44.60.

Zenas BioPharma (NASDAQ:ZBIO) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($1.46) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.01. During the same period last year, the firm earned ($0.80) earnings per share. On average, sell-side analysts anticipate that Zenas BioPharma will post -4.47 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Leon O. Moulder, Jr. bought 60,000 shares of the stock in a transaction dated Monday, May 18th. The stock was acquired at an average price of $16.88 per share, for a total transaction of $1,012,800.00. Following the acquisition, the chief executive officer owned 96,928 shares in the company, valued at approximately $1,636,144.64. This represents a 162.48% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last ninety days, insiders have acquired 120,000 shares of company stock valued at $2,080,000. Corporate insiders own 22.00% of the company’s stock.

Institutional Investors Weigh In On Zenas BioPharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ZBIO. Polar Capital Holdings Plc acquired a new stake in shares of Zenas BioPharma in the fourth quarter valued at approximately $38,402,000. Federated Hermes Inc. grew its position in shares of Zenas BioPharma by 45.9% during the fourth quarter. Federated Hermes Inc. now owns 2,715,578 shares of the company’s stock worth $98,603,000 after acquiring an additional 853,740 shares during the last quarter. EcoR1 Capital LLC acquired a new position in shares of Zenas BioPharma in the 4th quarter valued at $28,667,000. NEA Management Company LLC increased its holdings in shares of Zenas BioPharma by 28.9% in the 4th quarter. NEA Management Company LLC now owns 3,523,219 shares of the company’s stock valued at $127,928,000 after acquiring an additional 789,500 shares during the period. Finally, Bank of America Corp DE raised its position in Zenas BioPharma by 723.5% in the 1st quarter. Bank of America Corp DE now owns 388,347 shares of the company’s stock valued at $7,592,000 after purchasing an additional 341,187 shares during the last quarter.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.